Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety, determine the maximum tolerated dose (MTD) and schedule of IPI-493 in patients with hematologic malignancies.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Infinity Pharmaceuticals, Inc.
NCT04728893 · Hematologic Malignancies, Waldenstroms Macroglobulinaemia, and more
NCT05952804 · Hematologic Malignancies
NCT06823167 · Solid Malignancies, Hematologic Malignancies
NCT03838926 · Relapsed or Refractory Hematologic Malignancies
NCT05011422 · Pediatric Hematologic Malignancies
Johns Hopkins Sidney Kimmel Cancer Center
Baltimore, Maryland
Weill Cornell Cancer Center
New York, New York
M.D. Anderson Cancer Center
Houston, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions